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Repurposing existing drugs for new therapeutic indications can improve success rates and streamline 
development. Use of large-scale biomedical data repositories, including eQTL regulatory 
relationships and genome-wide disease risk associations, offers opportunities to propose novel 
indications for drugs targeting common or convergent molecular candidates associated to two or 
more diseases. This proposed novel computational approach scales across 262 complex diseases, 
building a multi-partite hierarchical network integrating (i) GWAS-derived SNP-to-disease 
associations, (ii) eQTL-derived SNP-to-eGene associations incorporating both cis- and trans- 
relationships from 19 tissues, (iii) protein target-to-drug, and (iv) drug-to-disease indications with 
(iv) Gene Ontology-based information theoretic semantic (ITS) similarity calculated between protein 
target functions. Our hypothesis is that if two diseases are associated to a common or functionally 
similar eGene - and a drug targeting that eGene/protein in one disease exists - the second disease 
becomes a potential repurposing indication. To explore this, all possible pairs of independently 
segregating GWAS-derived SNPs were generated, and a statistical network of similarity within each 
SNP-SNP pair was calculated according to scale-free overrepresentation of convergent biological 
processes activity in regulated eGenes (ITSeGENE-eGENE) and scale-free overrepresentation of common 
eGene targets between the two SNPs (ITSSNP-SNP). Significance of ITSSNP-SNP was conservatively 
estimated using empirical scale-free permutation resampling keeping the node-degree constant for 
each molecule in each permutation. We identified 26 new drug repurposing indication candidates 
spanning 89 GWAS diseases, including a potential repurposing of the calcium-channel blocker 
Verapamil from coronary disease to gout. Predictions from our approach are compared to known 
drug indications using DrugBank as a gold standard (odds ratio=13.1, p-value=2.49x10-8). Because 
of specific disease-SNPs associations to candidate drug targets, the proposed method provides 
evidence for future precision drug repositioning to a patient’s specific polymorphisms. 
Keywords: Drug repurposing; network analysis; drug repositioning; translational bioinformatics 
Supplementary material: http://lussiergroup.org/publications/drug_repurposing_by_eQTL 
                                               
* This work was supported in part by The University of Arizona Health Sciences CB2, the BIO5 Institute, 
The UA Cancer Center, and NIH (U01AI122275) 
† Authors contributed equally to this work 
* Corresponding authors contributed equally to this work  
© 2018 The Authors. Open Access chapter published by World Scientific Publishing Company, distributed 
under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC) 4.0 License. 
Pacific Symposium on Biocomputing 2019
308
 
B
io
co
m
pu
tin
g 
20
19
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.w
or
ld
sc
ie
nt
ifi
c.c
om
by
 U
N
IV
ER
SI
TY
 O
F 
A
RI
ZO
N
A
 o
n 
08
/0
6/
19
. R
e-
us
e a
nd
 d
ist
rib
ut
io
n 
is 
str
ic
tly
 n
ot
 p
er
m
itt
ed
, e
xc
ep
t f
or
 O
pe
n 
A
cc
es
s a
rti
cl
es
.
 
 
 
1.  Introduction 
Drug repurposing is an approach that investigates an approved drug for its potential efficacy as a 
treatment for other diseases1. This strategy can be cheaper, faster, and more efficient than de novo 
drug discovery since many preclinical and safety studies have already been completed2, 3.  
Some reported repurposing successes have relied on serendipitous clinical observation (i.e., 
Sildenafil/Viagra repurposed from pulmonary arterial hypertension to erectile dysfunction)4 while 
many others use disease-specific basic biology hypotheses where a single molecular factor has been 
independently associated with pathology in two or more diseases (i.e., FYN in solid tumor 
proliferation and Alzheimer’s)3. Employing scalable computational methods offers great potential 
for finding credible, novel, and hypothesis-free repurposing opportunities2, 5 by rapidly linking 
genetic risk factors and/or molecules perturbed during disease processes with known drug targets or 
other identified consequences of therapy2, 5-7. Several computational network analysis methods have 
been developed for drug repurposing, generally beginning from a seed set of well-described proteins 
or druggable targets. These then incorporate data from protein-protein and/or protein-drug 
biochemistry to propose new functional candidate molecules and drug activity based on presumptive 
physical interactions8, 9. Other methods examine gene expression changes to predict signature 
similarity between two diseases or between a disease and a drug exposure as a way to propose 
candidates10, 11. However, these methods are limited due to (i) typically relying on single-scale 
methodologies and (ii) focusing on coding DNA or their gene products. High-level integration of 
different data sources and knowledge are required to efficiently perform multiscale analysis for a 
more thorough approach to hypothesis-free drug repurposing, as well as integration of signals from 
noncoding areas of the genome.  
Genome-wide association studies (GWAS) represent a large potential source of information on 
genetic factors associated with disease risk or severity. However, about 50% of associations detected 
by GWAS have mapped to intergenic or noncoding sequences, suggesting altered regulatory 
capacity that remains difficult to interpret12. Fortunately, massive amounts of new data have been 
generated to address questions of noncoding function. These include the Genotype-Tissue 
Expression (GTEx) resource which mapped expression quantitative trait loci (eQTL) linking single 
nucleotide polymorphisms (SNP) to tissue-specific regulation of gene transcripts (eGenes)13. 
Colocalization of GWAS positional loci with these data14, 15 and/or with additional computational 
integration of data in other knowledge bases (e.g., protein-protein interaction networks, Gene 
Ontology (GO)16 annotations) shows that GWAS loci are enriched in putatively functional regions13, 
14. In addition, non-scalable and rate-limited studies have led to the discovery and characterization 
of several new disease-gene and disease-biological pathway mechanistic candidates17-21. 
Motivation. We have previously designed a multiscale network approach where SNPs from 
GWAS are connected to gene products and their annotations via eQTL22. In that study, we 
demonstrated that pairs of independently segregating GWAS SNPs associated to the same disease 
were significantly more likely to be involved in similar biological processes, colocalized with 
binding sites for the same transcription factor(s), and involved in chromatin interactions with each 
other when compared to pairs of SNPs where each SNP mapped to a different disease22. This is 
consistent with the prevailing idea that heterogeneous risk factors for a given complex disease will 
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display some form of coalescent properties and/or converge into a few non-random, key pathways 
involved in driving pathology, at least in many cases23, 24.  
In this study, we hypothesized that the downstream convergence of eQTL signals between 
highly similar SNP-SNP pairs can be leveraged to identify druggable molecular targets relevant to 
two diseases. Therapeutic modulation of that factor or the pathways it is involved with present a 
potential opportunity for drug repurposing. We computed similarity scores between risk factors 
(here, SNP-SNP pairs) based on information theoretic semantic (ITS) similarity of their associated 
gene ontology biological process terms (ITSGENE-GENE) and overrepresentation of shared or similar 
eGenes (ITSSNP-SNP). These data were integrated with drug targeting data25, 26. We further 
demonstrate that a scale-free resampling analysis of the resulting multiscale network discovers and 
prioritizes a significant number of known drug-to-indication relationships from our gold standard, 
i.e., known treatments for the network diseases. We also report a repurposing example with literature 
evidence confirming the plausibility of our findings. The drug repurposing approach we developed 
is different from the standard approaches (for a review refer to5) since, to our knowledge, no method 
has been yet published that integrates GWAS studies with eQTL associations as pairs, with gene 
ontology similarities leveraged to repurpose drugs across diseases incorporating both identical and 
similar pathological effectors and mechanisms.  
2.  Methods 
2.1.  Datasets 
    GWAS SNP-to-disease associations were obtained from the NHGRI-EBI GWAS Catalog27 
(11/20/2017) comprising 53,009 associations between 2,373 diseases/traits and 41,973 lead SNPs. 
    SNP-to-eGene associations. A comprehensive secondary cis- and trans-eQTL analysis by Fagny 
et al19 of the original raw data in the Genotype-Tissue Expression dataset28 (GTEx vers. 6.0) was 
used for linking SNPs to eGenes (http://networkmedicine.org:3838/eqtl/ ; 19 tissues). Fagny et al19 
adjusted p-values for multiple testing using Benjamini-Hochberg correction for cis- and trans- 
eQTL separately, and suggest retaining associations with False Discovery Rate (FDR)< 0.2. Sample 
genotypes were imputed by GTEx29, providing comprehensive overlap with the GWAS SNP set. 
The entire dataset included 5,896,354 associations between 1,114,453 SNPs and 21,971 eGenes.  
    Molecular drug-to-indication and target-to-drug and associations were downloaded from 
DrugBank API Portal (v1, 02/01/2018)25 and DrugBank (01/11/2017)26 respectively. The database 
consisted of 4,943 associations linking 1,133 drugs with 2,622 unstructured indications (i.e., 
diseases), as well as 11,978 associations linking 2,515 molecular targets with 5,623 drugs. 
    Gene Ontology (GO)30 (06/28/2016) provided 29,690 GO IDs in Biological Processes (GO-BP) 
and 120,779 associations involving 16,604 genes and 11,052 GO-BP IDs.  
2.2.  Building the drug repurposing network  
Briefly, we constructed an integrated multiscale biomolecular network connecting (i) diseases to (ii) 
SNPs to (iii) eGenes (eQTL transcripts) and cognate proteins intersected with both (iv-a) GO 
biological processes annotations (GO-BP) and (iv-b) drugs acting on the protein molecular targets 
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(Fig. 1). This network thus links each SNP to a set of eGenes and GO-BP terms. All possible SNP-
SNP pairs were created, filtered to remove those marking the same linkage locus, and SNP-SNP 
similarity was computed based on information theoretic semantic similarity of each eGene pair’s 
GO-BP terms (ITSeGENE-eGENE) and overrepresentation of the SNP-pair’s shared or similar eGenes 
(ITSSNP-SNP). Statistically prioritized SNP pairs within a disease were used for method and target 
validation (Fig. 1D). SNP pairs that spanned two diseases yet still showed an overrepresentation of 
shared and/or highly similar molecular downstream eGenes were suggested as repurposing 
candidates (Fig. 1C and 4B). 
Preprocessing the data was necessary for the integration of each element in the drug repurposing 
network. First, disease terms used by the GWAS Catalog and DrugBank required standardization 
into a formal representation (Methods 2.2.1), as well as an automated approach for match identical 
or highly similar diseases between these datasets (Methods 2.2.2). Next, we developed a method to 
establish the convergent biomolecular processes revealed by within-disease GWAS risk SNP-SNP 
pairs and compute similarity of these processes across diseases. We propose a nested information 
theoretic distance that considers the functional similarities between downstream eGenes of SNP 
pairs for prioritization of SNP pairs (Methods 2.2.3-5). Once the statistically significant eGene and 
SNP pairs are identified (FDR<0.05), we construct the biomolecular layer (Methods 2.2.6) and 
integrate this with the drug information (Methods 2.2.7) to create the Drug Repurposing Network. 
2.2.1.  Formal representation of disease terms (NHGRI GWAS and DrugBank). Multiple GWAS 
disease traits collected from the NHGRI GWAS Catalog were grouped into semantic disease 
bundles, each assigned to a SNOMED-Clinical Terms (CT) concept representation31. The GWAS 
curator-assigned Experimental Factor Ontology (EFO)27 was used to filter out non-disease 
phenotypes (e.g., pharmacogenomics responses, etc.) by retaining those under the branch 
EFO0000408: disease, reducing the 2,373 GWAS traits to 533 diseases. Text mining scripts and 
cross-mapping were used to link SNOMED-CT concepts to the EFO diseases, which were checked 
and curated into 262 bundles and coded to SNOMED-CT IDs. These bundles are referred to as 
“GWAS diseases” hereafter. We similarly coded 1,936 out of the 2,622 unstructured text disease 
terms of “DrugBank indications” to 2,054 distinct SNOMED IDs (Fig.1C). Note that one 
DrugBank indication can map to multiple SNOMED IDs. 
2.2.2.  Disease similarity computation. SNOMED-CT ontology was chosen because of its rich 
hierarchical relationships and high clinical coverage relevant to GWAS diseases and DrugBank 
indications. Disease-disease semantic similarity was determined by applying Lin’s information-
theoretic similarity (ITS) metric32 with Sánchez et al.’s information content (IC) estimation33 (Eq.1). 
By integrating these, ITS between diseases d1 and d2 (ITSDISEASE-DISEASE) can be calculated through 
Eq. 2, based on the hierarchical structure of the SNOMED-CT ontology. ITS similarity scores range 
from 0 to 1, where 1 corresponds to identity and 0 to complete dissimilarity. Two disease concepts 
with ITS>0.7 were considered similar. Using SNOMED, similarity is computed between every 
disease pair within the GWAS disease list as well as across the GWAS disease list and the DrugBank 
indication list (Eq. 2). Of note, drug repurposing is predicted between independent GWAS 
disease(s)-associated SNPs with non-trivial convergent eQTL mechanisms (Sections 2.2.3-5), in 
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which one of these GWAS diseases is similar or identical to a DrugBank indication 
(ITSGWAS_Disease−DrugBank_Indication(d1,d2)>0.7, applied Eq.2; Methods 2.2.7).    	   𝐼𝐶(𝑐) = 	  −𝑙𝑜𝑔, |./01/2(3)||245246/72(3)|	  89:;<	   _>?;@?A89 B	  	  (1)	  	  	  	  	  	  	  	  𝐼𝑇𝑆FGHIJHIKFGHIJHI(𝑑9, 𝑑N) = N	  ×	  GPQ>R;(ST,	  SU)VGP(ST)8GP(SU) 	  	  	  (2)	   	  
where |leaves(c)| is the number of leaf nodes under the concept c, |subsumers(c)| is the number of 
ancestor nodes above the concept, max_leaves is the total number of leaves covered by the root 
node, d is a disease, and lca is the least common ancestor to d1 and d2. 
2.2.3.  Information theoretic similarity between two eGenes using GO Biological Processes. We 
also applied the information-theoretic approach that we previously published34 to calculate 
functional similarity between any pair of eGenes (Fig.1A), i.e., ITSeGENE-eGENE. In GO, each gene 
product (gx), used here as the canonical cognate protein of an eGene transcript, can be annotated to 
a set of GO terms (T), denoted as T(gx). The similarity between eGene 1 (g1) and eGene 2 (g2) is 
calculated by semantic similarity between T(g1) and T(g2). For each GO-BP term (ti) associated to 
g1, the similarity score ITSGO-GO(ti, tj) is then calculated for every GO term (tj) associated to g2 (ti ∈ 
T(g2)) (Fig.1A) and use the maximum value among them (max); and vice-versa for g2. The similarity 
between two genes g1 and g2 is thus calculated as the average of all these maximum scores (Eq.3):  	   𝐼𝑇𝑆?YIZIK?YIZI(𝑔9, 𝑔N) = 	   ∑ :;<\]∈^(_U)`GaHbcdbcQef,e]Vg	  8	  ∑ :;<\f∈^(_T)`GaHbcdbcQef,e]Vg\]∈^(_U)\f∈^(_T) |a(hT)|8|a(hU)| 	   (3)	  
where |T(g1)| is the cardinality of the set T(g1). The ITSeGENE-eGENE output has a range between 0 and 
1, where 0 indicates two genes having no similar GO annotations and 1 indicates two genes having 
identical GO annotations.  
2.2.4.  Information theoretic similarity between SNPs. The ITS of a SNP-SNP pair was calculated 
where both are (i) associated with at least one of the 262 GWAS diseases (Methods; 2.1.1) and (ii) 
regulate at least one eGene. Our previously published calculation22 of similarity between a pair of 
SNPs (ITSSNP-SNP) is an extension of the ITSeGENE-eGENE. Since every SNP can be associated with 
multiple eGenes and every eGene can be associated with multiple GO terms, the ITSSNP-SNP is a 
nested calculation that leverages the ITSeGENE-eGENE scores. It is based on the average similarity of 
the set of genes associated by eQTL with the two SNPs, as shown in Eq.4 below:  	   𝐼𝑇𝑆HZjKHZj(𝑠9, 𝑠N) = 	   ∑ :;<_]∈b(2U)`GaH/blmld/blmlQhf,h]Vg	  8	  ∑ :;<_f∈b(2T)`GaH/blmld/blmlQhf,h]Vg_]∈b(2U)_f∈b(2T) |Y(AT)|8|Y(AU)| 	  (4)	  
where SNP s1 was associated with a set of genes G(s1), and |G(s1)| is the cardinality of the set 
G(s1), similarly for s2. The ITSeGENE-eGENE is the similarity of two genes computed with Eq.3. 
Likewise, the ITSSNP-SNP has a score ranging from 0 to 1; a value of 1 indicates two SNPs of perfect 
similarity, and 0 refers to two SNPs of null functional similarity. 
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Fig. 1.  Overview of the construction, computational prioritization, and validation of the drug repurposing 
network. A) ITS computation. We applied ITS to compute the similarity between GO-BPs, SNPs, and genes through 
a cascade process as described in Methods 2.2.3-5. This began construction of the biomolecular network layer. B) 
Integration of multiscale biomolecular associations using GWAS diseases, SNPs, and eGenes as nodes. The 
associations (edges) between nodes were obtained by extracting GWAS disease-to-SNP, and SNP-to-eGene (SNP-
eG) relationships from the database resources described (Methods 2.1). The biomolecular network was then filtered 
to remove SNP-SNP pairs not meeting the introduced criteria (Edge Legend, Methods 2.2.6.). ITSSNP-SNP is computed 
as in Eq.4 considering all the eGenes extracted from eQTL data and the network was further refined to include only 
significantly similar eGene-eGene pairs, i.e. ITSSNP-SNP and ITSeGENE-eGENE (Eq.3) False Discovery Rate (FDR) <0.05. 
Drug-eGene and Drug-indication associations extracted from Drugbank (drug information layer) are included to 
obtain the final drug-repurposing network. C) Network validation. The drug repurposing network is validated by 
querying if the network predicted a significantly high number of gold standard treatments for GWAS diseases. Two 
conditions of validation are proposed, one stringent and one more relaxed (**). D) Drug repurposing patterns. We 
extracted GWAS disease pairs and the related convergent mechanisms where at least a gold standard treatment was 
predicted for one of the two GWAS diseases. The approach predicts new candidate therapies by repositioning drugs 
across these GWAS disease pairs.  
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2.2.5.  Scale-Free permutation for FDR estimation of ITS. 10,000 and 100,000 conservative scale-
free permutations were performed to estimate statistical significance of the ITSeGENE-eGENE and 
ITSSNP-SNP scores (~500,000 core hours), respectively. In each permutation, the node degree of every 
node in the gene-GO annotation network was preserved (each specific gene retained the node degree 
of GO term associations and vice-versa). Multiplicity of prioritization was controlled by Benjamini-
Hochberg with a cutoff of FDR≤0.05 (p.adjust for both ITSeGENE-eGENE and ITSSNP-SNP).  
2.2.6.  Biomolecular network layer construction (Fig.1). The drug repurposing network construction 
starts by defining its biomolecular layer. This level associates GWAS diseases, SNPs, and 
molecular targets (Fig.1A). Disease-to-SNP edges were obtained from GWAS lead SNPs, and 
SNP-to-regulated molecular target (eGene) edges were obtained from eQTL data as described in 
Methods 2.1.2. This produced a network of 9,750 associations between 8,955 SNPs and 235 unique 
diseases, where each of the retained SNPs was also associated with at least one eGene via eQTL. 
All SNP-SNP pairs were generated and filtered to remove SNP pairs (i) separated by less than 5Mb, 
(ii) in linkage disequilibrium with one another (r2>0.01) according to HapMap and 1000 Genomes 
CEU data, and/or (iii) SNP pairs where both mapped within the Major Histocompatibility Complex 
(MHC; Chr6: 28,477,797-33,448,355, ±2 Mb; GRCh37). SNP-SNP pairs where only one SNP 
mapped to the MHC were retained. This was done to remove SNP pairs trivially marking the same 
locus. Similarity is computed (ITSSNP-SNP) for each retained SNP pair according to Eq.4 (Methods 
2.2.4). Focusing only on the SNP pairs that were statistically significant (ITSSNP-SNP; FDR<0.05), 
ITSeGENE-eGENE is computed (Eq.3) to further filter. SNP pairs that satisfied both ITSSNP-SNP and 
ITSeGENE-eGENE at FDR<0.05 were considered as having convergent biological mechanisms and used 
to construct the final biomolecular network.  
2.2.7.  Construction of the drug repurposing network. The final network construction step involves 
the integration of drug knowledge (Fig.1B) with the biomolecular level by matching protein-coding 
eGenes with the molecular targets of drugs acquired from DrugBank (Methods 2.1.3). In this step, 
the disease indications are included for these drugs, as they serve to validate our predictions when 
recapturing known indications (validation, Methods 2.3) and to identify novel opportunities 
predicted by our method that can be used for drug repurposing (Methods 2.4).  
2.3.  Validation of the drug repurposing network  
Before analyzing potential drug repurposing candidates, we validated our drug repurposing network 
by determining whether known drug indications for the included GWAS diseases could be inferred 
from the network above the chance expectation (Fig.1C). To this end, a Fisher’s Exact Test (FET) 
is performed considering: (i) all druggable molecular targets (DMTs) and (ii) all druggable diseases 
(DD). In this validation, a DMT was defined as any eGene that has at least one drug in DrugBank 
targeting the cognate protein, and that the drug is indicated for one or more of the 262 GWAS 
diseases defining our set (Methods 2.2). A DD is defined as any GWAS diseases in the network 
associated with at least one target eGene found in DrugBank, and therefore corresponds to all the 
GWAS diseases that could theoretically be validated using these databases. In this way, we can 
determine how many of the theoretical combinations of DMTs and DDs (DMTs*DDs) are predicted 
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by analysis of significant eGenes associated with prioritized SNP pairs with convergent 
mechanisms. The enrichment of gold standard drug indications among the predictions is conducted 
assuming that the GWAS disease-eGenes analysis can, in principle, discover any drug targets in 
DrugBank. We constructed the contingency table to perform the FET by counting the number of 
DMT-DD interactions (i) present/not present in Drugbank vs (ii) included/not included in our final 
ITS-filtered network (Fig.1C). 
The validation procedure includes similarity between GWAS diseases and indications (Fig.1D; 
ITSGWAS_Disease−GWAS_Disease, Eq.2; Methods 2.2.2). The network validation procedure is then 
conducted by applying two additional conditions, one stringent and one more relaxed (Fig.1D), 
using DrugBank as a gold standard. First, convergent mechanisms between two SNPs associated 
with the same GWAS are prioritized (ITSGWAS_Disease−GWAS_Disease>0.7), i.e., similar SNP pairs 
(ITSSNP-SNP FDR<0.05) with eGene pairs (ITSeGENE-eGENE FDR<0.05), and the number of eGene-
GWAS disease associations that were identical or similar (ITSGWAS_Disease−DrugBank_Indication>0.7) to the 
related molecule-indication associations found in DrugBank were counted (Fig.1D). In the relaxed 
condition, the same procedure is applied, but without the constraint that both SNPs in the prioritized 
pair must map to the same disease (Fig.1D). 
2.4.  Drug repurposing pattern identification 
Drug repurposing candidates are identified by analyzing specific network patterns as illustrated in 
Fig.1D. We prioritized all subnetworks involving pairs of GWAS diseases related to convergent 
mechanism in which at least one eGene was targeted by a drug known to treat one of the two GWAS 
diseases or a similar (ITSGWAS_Disease−DrugBank_Indication ≤0.7) disease. Thus, if the drug is prescribed as 
a treatment for two diseases dissimilar in the pair (ITSGWAS_Disease−GWAS_Disease>0.7), then it is 
predicted as a repurposing candidate across the two GWAS diseases. 
3.  Results and discussion  
3.1.  Overall results and visualization 
The drug repurposing network (Fig.2A) comprises 1,865 nodes and 15,655 edges (Fig.2B) and was 
obtained after considering the similarity of 479,896 SNP-SNP pairs. 74,803 SNP pairs are 
prioritized with significant convergent biomolecular mechanisms (ITSSNP-SNP with FDR<0.05, Eq.4; 
Methods 2.2.5). The list of similar SNP-pairs is further constrained to those with an association to 
at least one disease for which an indication is known in DrugBank, resulting in 9,418 retained SNP 
pairs, their associated significant eGene pairs (ITSeGENE-eGENE with FDR<0.05, Methods 2.2.3), and 
drug information (Methods 2.2.7). All retained SNP pairs marked two independently segregating 
disease loci, based on the positional and linkage filters applied in Methods 2.2.6. SNP pair similarity 
was driven by both cis- and trans-eQTL associations, with 8,329 SNP pairs prioritized through 
regulation of similar eGenes found in cis to each SNP, and 1,089 SNP pairs prioritized based on at 
least one trans-regulated eGene by one of the SNPs (Fig.2A). Fig.2B shows details of the network 
nodes and edges. While they remain a minority, having 12% of prioritized SNP pairs reliant on 
trans-eQTL relationships highlights the importance of including these complex regulatory data, as 
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these would have been overlooked by focusing exclusively on those genes near the GWAS SNP. 
The subnetwork relevant for drug repurposing comprises only the SNP-pairs for which their 
prioritized eGenes code for the protein target of an existing drug (Fig.2C). 
 
3.2.  Network validation results 
We validated our network by calculating the enrichment of drug targets predicted by our method 
(Methods 2.3) over drug targets reported in a curated database gold standard (DrugBank). First, 
identical or similar disease indications matched to any of the 262 GWAS diseases are extracted, 
which resulted in 127 “druggable” diseases (DD) together with their 1,336 associated druggable 
molecular targets (DMT). This yielded 169,672 eGene-disease combinations that could potentially 
be predicted (DMT*DD). Assuming the stringent criterion where DrugBank’s annotated drug 
indication must be identical or similar to the GWAS disease and both SNPs in the prioritized SNP-
SNP pair must be associated to that same GWAS disease, our method predicted 56 relationships 
involving DMTs and GWAS diseases. DrugBank included 2,783 DMT-DD associations with 10 
overlapping (Fisher’s Exact Test-FET p=2.5x10-8; odds ratio=13.1). When considering the more 
relaxed criterion of high similarity between gold standard diseases and predicted indications, we 
found 29 overlapping, from a total of 299 potential predictions (FET p= 3.6x10-14; odds ratio= 6.5).   
 
Fig. 2. Drug Repurposing Network. A) Comprehensive biomolecular network comprising significant convergent 
cis- and trans-eQTL mechanisms between GWAS disease-associated SNPs (ITSSNP-SNP FDR<0.05; ITSeGENE-eGENE 
FDR<0.05), for which there exists indications in DrugBank (i.e., the molecular target of Drugi is the protein 
transcribed by at least one eGene associated by eQTL to SNP-SNP Pairx; Fig.1B; Methods 2.2). B)  Tables 
summarizing the number of nodes and edges of the network shown in panel A; for each edge type we also reported 
the mean node outdegree. C) Prioritized subset of the network in panel A relevant for drug repurposing because it 
satisfies one additional criteria: the disease indication of a Drugi is identical or similar to the GWAS disease 
associated to the SNP-SNP Pairx related to the eGene targeted by the Drugi (Fig.1C; Methods 2.4; 
ITSGWAS_Disease−DrugBank_Indication>0.7). In Supplementary Material -Figure S1, we reported a high-resolution 
version of this network with labeled network node names.   
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Fig.3A illustrates a drug target for Rheumatoid Arthritis (RA) that was predicted by eQTL 
similarity of two distinct GWAS SNPs35 (ITSSNP-SNP FDR=0.0007) and confirmed in DrugBank as 
the known target of Etanercept indicated for Polyarticular Juvenile Idiopathic Arthritis (PJIA)36, 37. 
These two RA SNPs (rs72717009 and rs4239702) affect the expression of FCGR2C and CD40 
respectively. The gene products of FCGR2C and CD40 are annotated to highly similar biological 
processes (ITSeGENE-eGENE FDR=0.01), suggesting a convergent mechanism revealed by these two 
independently segregating factors. Since RA and PJIA are highly similar diseases (ITSRA-PJIA=0.78), 
our approach could correctly predict Etanercept as a treatment for RA37. 
3.3.  Drug repurposing results 
Following the procedure in Methods 2.4, we extracted the GWAS diseases having convergent 
mechanisms (ITSSNP-SNP FDR<0.05 and ITSGENE-GENE FDR<0.05) with one of the GWAS diseases 
for which at least one gold standard indication was present in the network. In detail, we identified 
181 distinct GWAS disease pairs involving 90 diseases. 19 of these diseases had a molecularly-
targeted treatment indicated in DrugBank that matched the eGene-prioritized molecular targets (i.e., 
GWAS diseaseA shown in Fig.1D). 89 diseases had new drug candidates identified by our network, 
potentially allowing repurposing (i.e., GWAS diseaseB in Fig.1D). We extracted 1,288 patterns 
(Supplementary Material -Table S1) including 26 drug candidates relevant to at least one of the 
89 GWAS diseases. The subnetwork obtained by considering the drug repurposing patterns is 
depicted in Fig.2B and comprises 628 nodes (90 GWAS diseases, 253 SNPs, 108 eGenes, 26 drugs 
and 151 indications) and 1,758 edges. Within the 391 SNP-SNP pairs (edges), 25 were prioritized 
based on at least one trans-eQTL association and 366 are driven exclusively by cis-eQTL 
associations. Tissue source of each eQTL association are provided in Table S1. As eQTL detection 
power varied between tissues in our input and multi-organ pathologies are common in complex 
diseases, we chose not to restrict our results to only those with shared or overlapping tissue sources. 
However, as candidates are considered more closely, these filters may allow prioritization and/or a 
cleaner set of hypotheses. 
Fig.3B illustrates Verapamil as a candidate drug target for gout repositioned from coronary 
artery disease that was predicted by eQTL similarity of their respective distinct GWAS SNPs 
 
Fig. 3. Examples of prediction by eQTL signal convergence across distinct chromosomes. A) Gold standard 
validation. In the drug repurposing network, we could confirm Etanercept as standard treatment for Rheumatoid 
arthritis. B) Drug repurposing. Our approach was able to predict Verapamil as a new potential treatment for gout, for 
which a retrospective study reports lower incidence of gout.   
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(ITSSNP-SNP FDR=0.000039). The proposed method predicted that KCNH2 is involved in similar 
biological processes as KCKN7 (FDR ITSeGENE-eGENE FDR<10-4). Verapamil is a calcium channel 
blocker and inhibitor of the protein Potassium voltage-gated channel subfamily H member 2 
(KCNH2)38. It is a class IV anti-arrhythmia agent currently used to treat hypertension, angina, and 
cluster headache. The cross-disease prioritized SNP pair indicates that variation at rs13232179 
(coronary artery disease39) modulates expression of KCNH2 in tibial artery and that variation at 
rs10791821 (gout40) modulates expression of KCNK7 in tibial artery, transverse colon, esophagus 
muscularis, and thyroid. Functional similarity between KCNH2 and KCNK7 suggests that effective 
pathway modifying medications may play a role in both conditions. Supporting this prediction, 
studies have demonstrated that other calcium channel blockers are associated with a lower risk of 
incident gout41.  
4. Limitations and future studies 
Currently, our method cannot detect if the effect of the expression from eQTL studies is concordant; 
and so, the proposed method may predict adverse events as well as drug repurposing opportunities. 
For example, Adalimumab (Fig.2C), currently prescribed for inflammatory bowel disease, is 
predicted as a possible treatment for Multiple Sclerosis (MS). However, anecdotal cases report 
worsening of MS patients treated with this drug42. Regulation of eGenes in distinct tissues may also 
have important biological consequences. Future studies will focus on (i) experimental validation of 
select candidates, (ii) to provide the data with filtering and analysis tools as an online public 
repository, and (iii) the integration of directional eQTL information in the presence of specific SNP 
variants to determine if these cases can be predicted. 
5. Summary and conclusion 
Drug repurposing offers novel venues to use currently available or investigational drugs. We 
developed a computational drug repurposing approach leveraging several data and knowledge 
resources, by integrating GWAS studies, eQTL data, drug information, and GO similarities in a 
multi-partite hierarchical network. Our approach is anchored on the identification of convergent cis- 
and trans- eQTL targets across distinct disease-associated polymorphisms. These repurposings are 
distinct from previous approaches in that we integrate convergent downstream cis- and trans-eQTL 
signals from any polymorphism, inclusive of intergenic regions. This automatically suggests drug 
repurposing through shared molecular target candidates identified across diseases, beyond the 
straightforward “host” or “nearest” gene overlap (e.g., protein-interaction networks). Our study 
demonstrates that GWAS and eQTL-derived networks can predict a significant number of gold 
standard indications and novel drug repurposing suggestions. Because of specific disease SNPs-
associations to candidate drug targets, the proposed method provides evidence for future precision 
drug repositioning to a patient’s specific polymorphisms. 
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